Prolonged response of widely metastatic HER2-positive colon cancer to trastuzumab therapy
| Autor: | W Jeffrey Edenfield, Julie C. Martin, W Larry Gluck, David Arguello, Ki Y Chung |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
Oncology medicine.medical_specialty business.industry Colorectal cancer Gastroenterology medicine.disease digestive system diseases 03 medical and health sciences 030104 developmental biology 0302 clinical medicine Trastuzumab 030220 oncology & carcinogenesis Internal medicine medicine skin and connective tissue diseases business medicine.drug |
| Zdroj: | Colorectal Cancer. 6:57-61 |
| ISSN: | 1758-1958 1758-194X |
| Popis: | Emerging evidence suggests a small subset of late-stage colon cancer driven by HER2, a biomarker routinely evaluated in select breast and gastric cancers, may respond to HER2-targeted therapy. Herein, we describe a 49-year-old male with widely metastatic colon cancer originating in the sigmoid colon. After failing standard therapy, a biopsy specimen of the tumor was evaluated for novel biomarkers using molecular profiling. After identification of ERBB2 (HER2) amplification using in situ hybridization, the patient subsequently received a trial of trastuzumab monotherapy and experienced a dramatic and durable response. This report builds on our understanding of using precision oncology to improve survival in metastatic colon cancer. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|